• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Skip to investors navigation

Scholar Rock

Discovery and Development of Innovative Medicines

  • Careers
  • Newsroom
  • Contact Us
  • For HCPs
    • Grants and Sponsorships
    • Investigator-Initiated Studies
    • Expanded Access
    • Additional Resources and Information
    • Contact
  • Patients & Families
    • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access

    Learn about our commitment to creating possibilities for those living with serious disease.

    Patients & Families

  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
      • Fellowship
    • Management Team
    • Board of Directors
    • Grants and Sponsorships
    • Investigator-Initiated Studies

    Meet Scholar Rock, a biopharmaceutical company committed to improving lives.

    Our Company

  • Our Science
    • Our Science
    • Platform
    • Publications & Posters

    Discover how our breakthrough approach treats complex disease at its biological root.

    Our Science

  • Our Pipeline
    • Our Pipeline
    • Neuromuscular
      • Spinal Muscular Atrophy
    • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Our Medicine
    • ISEMBYLD™
  • Investors & Media
    • Investor Overview
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
HomePatients & FamiliesClinical Trials

Clinical Trials

The process from lab to patient

We believe in our science and its potential to change patients’ lives. Clinical trials are a critical step in bringing a new therapy from our in-house laboratory to the world.

Read below for important background information and the most recent updates on our clinical trials. Patients seeking more information on potential clinical trials should contact their physician.

Neuromuscular

Opal

OPAL

Spinal Muscular Atrophy

Initiated, recruiting

OPAL is a Phase 2 double-blind study designed to evaluate apitegromab in patients under two years of age who have been or are continuing to be treated with any currently approved SMN therapy, including onasemnogene abeparvovec.

Learn more about OPAL at clinicaltrials.gov

ONYX

ONYX

Spinal Muscular Atrophy

Active, not recruiting

ONYX is an open-label Phase 3 study designed to assess the long-term safety and efficacy of apitegromab in participants with Type 2 and Type 3 SMA who have completed the TOPAZ or SAPPHIRE trial.

Learn more about ONYX at clinicaltrials.gov

FORGE

FORGE

Facioscapulohumeral Muscular Dystrophy

Active, recruiting

The FORGE clinical study is evaluating apitegromab, Scholar Rock’s investigational muscle-targeted treatment, to find out how it impacts muscle size and function in people with FSHD, and how well it works compared to a placebo. Doctors also want to learn how people respond to apitegromab and how safe it is.

Learn more about FORGE

Expanded Access Policy

View Our Expanded Access Policy

Patients seeking more information on potential clinical trials should contact their physician.

Footer

Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142

Phone: 857.259.3860
[email protected]

LinkedIn X, formally Twitter

SCHOLAR ROCK and the S logo are trademarks of Scholar Rock, Inc.

© 2026 All Rights Reserved

  • Community Guidelines
  • Expanded Access
  • State Regulations & Disclosures
  • Privacy Policy
  • Terms of Use

We are Scholar Rock.

A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

Learn More About Our Pipeline

  • Community Guidelines
  • Expanded Access
  • State Regulations & Disclosures
  • Privacy Policy
  • Terms of Use
logo
  • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access
  • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
      • Fellowship
    • Management Team
    • Board of Directors
    • Grants and Sponsorships
    • Investigator-Initiated Studies
  • Our Science
    • Platform
    • Publications & Posters
  • Our Pipeline
    • Neuromuscular
      • Spinal Muscular Atrophy
    • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Our Medicine
    • ISEMBYLD™
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
  • Careers
  • Newsroom
  • Contact Us
  • For HCPs
    • Grants and Sponsorships
    • Investigator-Initiated Studies
    • Expanded Access
    • Additional Resources and Information
    • Contact

You are now leaving the Scholar Rock website.

This external link is provided for your convenience. Scholar Rock is not responsible for content on external websites.

Continue